Beigelman Leonid 4
4 · Aligos Therapeutics, Inc. · Filed Mar 17, 2023
Insider Transaction Report
Form 4
Beigelman Leonid
DirectorPresident
Transactions
- Award
Stock Option (Right to Buy)
2023-03-15+169,500→ 169,500 totalExercise: $1.34Exp: 2033-03-15→ Common Stock (169,500 underlying)
Footnotes (1)
- [F1]1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.